特立帕肽和降钙素治疗中国绝经后骨质疏松症患者的效果比较

被引:12
作者
戴克戎 [1 ]
陈德才 [2 ]
章振林 [3 ]
张克勤 [4 ]
王炳强 [5 ]
贺良 [6 ]
刘波 [6 ]
徐华梓 [7 ]
胡雅莉 [8 ]
曹永平 [9 ]
Yu M [10 ]
Blair JM [11 ]
骆天红 [12 ]
机构
[1] 上海交通大学医学院第九人民医院骨科
[2] 四川大学华西医院内分泌代谢科
[3] 上海市第六人民医院骨质疏松科
[4] 南京医科大学第一附属医院内分泌科
[5] 北京友谊医院骨科
[6] 北京积水潭医院创伤骨科
[7] 温州医学院第二附属医院和育英儿童医院骨科
[8] 南京市鼓楼医院妇产科
[9] 北京大学第一医院骨科
[10] 礼来加拿大公司
[11] 礼来澳大利亚公司洲际信息科学部
[12] 中国上海市礼来亚洲公司
关键词
绝经后骨质疏松症; 特立帕肽; 降钙素; 骨密度; 血清骨钙素;
D O I
暂无
中图分类号
R580 [];
学科分类号
摘要
目的比较特立帕肽[重组人甲状旁腺激素(1-34);rhPTH(1-34)]与降钙素鼻喷剂对中国绝经后妇女骨质疏松症的治疗效果。方法特立帕肽组患者(N=217)采用特立帕肽20μg/d皮下注射,降钙素组患者(N=110)用鲑鱼降钙素鼻喷剂200 IU/d滴鼻,疗程均为24周。2组患者均每天补充≥500 mg的钙和200~400 IU的维生素D。主要终点是基线至终点腰椎BMD的变化率。结果特立帕肽组患者腰椎BMD从基线到终点的变化率与降钙素组相比差异有统计学意义(P<0.000 1)。与降钙素组相比,特立帕肽组患者从基线到终点血清骨钙素水平明显升高(P<0.000 1)。2组患者全髋和转子BMD变化率的差异均无统计学意义。2组患者出现不良事件(AE)者均较少,特立帕肽组AE较降钙素组多。结论特立帕肽增加腰椎BMD的效果优于降钙素,2种疗法均安全且耐受性好。
引用
收藏
页码:23 / 31
页数:9
相关论文
共 14 条
[1]
Response to teriparatide in patients with baseline 25-hydroxyvitamin D insufficiency or sufficiency [J].
Dawson-Hughes, Bess ;
Chen, Peiqi ;
Krege, John H. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (12) :4630-4636
[2]
Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: An 18-month, multicenter, open-label, prospective study [J].
Adachi, Jonathan D. ;
Hanley, David A. ;
Lorraine, Joanne K. ;
Yu, Maria .
CLINICAL THERAPEUTICS, 2007, 29 (09) :2055-2067
[3]
Reduction in the risk of developing back pain persists at least 30 months after discontinuation of teriparatide treatment: a meta-analysis [J].
Nevitt, M. C. ;
Chen, P. ;
Kiel, D. P. ;
Reginster, J. -Y. ;
Dore, R. K. ;
Zanchetta, J. R. ;
Glass, E. V. ;
Krege, J. H. .
OSTEOPOROSIS INTERNATIONAL, 2006, 17 (11) :1630-1637
[4]
Teriparatide vs. calcitonin in the treatment of Asian postmenopausal women with established osteoporosis [J].
Hwang, JS ;
Tu, ST ;
Yang, TS ;
Chen, JF ;
Wang, CJ ;
Tsai, KS .
OSTEOPOROSIS INTERNATIONAL, 2006, 17 (03) :373-378
[5]
Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy [J].
Dobnig, H ;
Sipos, A ;
Jiang, YB ;
Fahrleitner-Pammer, A ;
Ste-Marie, LG ;
Gallagher, JC ;
Pavo, I ;
Wang, JY ;
Eriksen, EF .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (07) :3970-3977
[6]
An estimate of the worldwide prevalence, mortality and disability associated with hip fracture [J].
Johnell, O ;
Kanis, JA .
OSTEOPOROSIS INTERNATIONAL, 2004, 15 (11) :897-902
[7]
Mortality after osteoporotic fractures [J].
Johnell, O ;
Kanis, JA ;
Odén, A ;
Sernbo, I ;
Redlund-Johnell, I ;
Petterson, C ;
De Laet, C ;
Jönsson, B .
OSTEOPOROSIS INTERNATIONAL, 2004, 15 (01) :38-42
[8]
Calcitonin for the long-term prevention and treatment of postmenopausal osteoporosis [J].
Body, JJ .
BONE, 2002, 30 (05) :75S-79S
[9]
Epidemiology and outcomes of osteoporotic fractures [J].
Cummings, SR ;
Melton, LJ .
LANCET, 2002, 359 (9319) :1761-1767
[10]
Standardization of bone mineral density at femoral neck, trochanter and Ward's triangle [J].
Lu, Y ;
Fuerst, T ;
Hui, S ;
Genant, HK .
OSTEOPOROSIS INTERNATIONAL, 2001, 12 (06) :438-444